These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7981581)

  • 1. High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure.
    Pecherstorfer M; Zimmer-Roth I; Weidinger S; Irsigler K; Halbmayer WM; Ulrich W; Fischer M; Baumgartner G
    Clin Investig; 1994 Jul; 72(7):522-5. PubMed ID: 7981581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
    Raina V; Sharma A; Kumar R; Bhargava M
    Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloma kidney: improved renal function following long-term chemotherapy and hemodialysis.
    Dahlberg PJ; Newcomer KL; Yutuc WR; Smith MJ
    Am J Nephrol; 1983; 3(4):242-3. PubMed ID: 6614074
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature.
    Reiter E; Kalhs P; Keil F; Rabitsch W; Gisslinger H; Mayer G; Worel N; Lechner K; Greinix HT
    Ann Hematol; 1999 Apr; 78(4):189-91. PubMed ID: 10348151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose intravenous melphalan in advanced multiple myeloma.
    Bäck H; Lindblad R; Rödjer S; Westin J
    Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute renal failure in multiple myeloma.
    Booth LJ; Minielly JA; Smith EK
    Can Med Assoc J; 1974 Aug; 111(4):334-5. PubMed ID: 4850422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study).
    Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ
    Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
    Hada R; Poudyal B; Sharma A; Khatri R
    JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
    Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):145-50. PubMed ID: 19406725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furosemide in acute oliguric renal failure. A controlled trial.
    Kleinknecht D; Ganeval D; Gonzalez-Duque LA; Fermanian J
    Nephron; 1976; 17(1):51-8. PubMed ID: 778649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
    Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
    Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
    Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
    Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Maintenance hemodialysis in IgD- lambda -type multiple myeloma associated with severe renal failure].
    Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H
    Nihon Jinzo Gakkai Shi; 1994 Feb; 36(2):177-81. PubMed ID: 8139151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival of patients with multiple myeloma and acute renal failure at presentation.
    Lazarus HM; Adelstein DJ; Herzig RH; Smith MC
    Am J Kidney Dis; 1983 Mar; 2(5):521-5. PubMed ID: 6402926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure.
    Rebibou JM; Caillot D; Casasnovas RO; Tanter Y; Maillard N; Solary E; Rifle G; Guy H
    Bone Marrow Transplant; 1997 Jul; 20(1):63-5. PubMed ID: 9232259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.